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Lack of involvement of nucleotide excision repair gene
polymorphisms in colorectal cancer
R Mort1, L Mo1, C McEwan1 and DW Melton*,1
1Sir Alastair Currie Cancer Research UK Laboratories, Molecular Medicine Centre, University of Edinburgh, Western General Hospital, Crewe Road,
Edinburgh EH4 2XU, UK
DNA repair has an essential role in protecting the genome from damage by endogenous and environmental agents. Polymorphisms
in DNA repair genes and differences in repair capacity between individuals have been widely documented. For colorectal cancer, the
loss of mismatch repair gene activity is a key genetic determinant. Nucleotide excision repair (NER), recombination repair (RR) and
base excision repair (BER) pathways have critical roles in protection against other cancers, and we wished to investigate their role in
colorectal cancer. We have compared the frequency of polymorphisms in the NER genes, XPD, XPF, XPG, ERCC1; in the BER gene,
XRCC1; and in the RR gene, XRCC3; in colorectal cancer patients and in a control group. No significant associations were found for
any of the NER gene polymorphisms or for the XRCC1 polymorphism. The C allele (position 18067) of the XRCC3 gene was weakly
but significantly associated with colorectal cancer (odds ratio 1.52, 95% confidence interval 1.04–2.22, P¼ 0.03). For all patients who
were heterozygous for any of the repair genes studied, tumour tissue was investigated for loss of heterozygosity (LOH). Only one
example of LOH was found for all the genes examined. From the association and LOH data, we conclude that these genes do not
have an important role in protection against colorectal carcinogenesis.
British Journal of Cancer (2003) 89, 333–337. doi:10.1038/sj.bjc.6601061 www.bjcancer.com
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Several complementary DNA repair mechanisms have evolved to
protect the genome from DNA damage caused by endogenous or
environmental agents, which could lead to mutations and
carcinogenesis (Friedberg, 2001). DNA repair capacity varies
between individuals in the general population (for a review, see
Berwick and Vineis, 2000). An increasing number of DNA repair
gene polymorphisms are being described and their involvement in
carcinogenesis is being investigated. For colorectal cancer, the
importance of mutations in mismatch repair (MMR) genes has
been extensively documented. MMR gene defects account for 15%
of sporadic colorectal cancer, and germline mutations in MMR
genes are the cause of hereditary nonpolyposis colon cancer (for a
review, see Jiricny and Nystrom-Lahti, 2000). The role of
additional low-penetrance genes in colorectal cancer susceptibility
has been recently reviewed (de Jong et al, 2002). We wished to
investigate the hypothesis that alterations in other DNA repair
pathways were also important genetic determinants of colorectal
carcinogenesis.
The nucleotide excision repair (NER) pathway deals with UV
light-induced DNA damage (for a review, see Wood, 1997). In the
inherited disorder, xeroderma pigmentosum, NER deficiency
results in a 1000-fold increased incidence of skin cancer, but also
a 20-fold increase in internal tumours (Friedberg et al, 1995),
indicating that NER is also important in the repair of endogenous
DNA damage. Indeed, the digestive tract contains materials such as
lipid peroxidation by-products that can react with DNA to
generate bulky adducts that are recognised by NER (Friedberg
et al, 1995). Amino-acid variants in NER genes are common in the
general population (Shen et al, 1998) and some, such as the XPD
exon 23 polymorphism, have been associated with reduced DNA
repair capacity (Lunn et al, 2000; Qiao et al, 2002). We have
reported a significant association between polymorphisms in
exons 6, 22 and 23 of the XPD gene and melanoma in patients
under 50 (Tomescu et al, 2001). Significant association between
NER gene polymorphisms and other cancers, but not colorectal,
have also been reported: glioma (Chen et al, 2000); lung (Chen et al,
2002; Park et al, 2002); squamous cell carcinoma of the head and
neck (SCCHN; Sturgis et al, 2002).
The XRCC1 gene is involved in the repair of single-strand DNA
breaks and in base excision repair (BER) of damaged bases caused
by endogenous and exogenous oxidants, including tobacco smoke.
XRCC1 polymorphisms have been associated with SCCHN (Sturgis
et al, 1999), pancreatic adenocarcinoma (Duell et al, 2002), lung
cancer (Chen et al, 2002) and bladder cancer (Stern et al, 2002).
There is also a single report of a significant association with
colorectal cancer (reviewed by de Jong et al, 2002). The XRCC3
gene, a paralogue of RAD51, is involved in recombination repair
(RR) and is required for genome stability (Griffin et al, 2000).
XRCC3 polymorphisms have been associated with melanoma
(Winsey et al, 2000), bladder cancer (Matullo et al, 2001a; Stern
et al, 2002) and SCCHN (Shen et al, 2002).
Loss of heterozygosity (LOH) of tumour suppressor genes, such
as p53, APC and BRCA1, is an important step in carcinogenesis.
LOH for NER genes has been reported as a common occurrence in
a range of carcinomas (Takebayashi et al, 2001), and we also
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wished to study LOH of NER genes in our colorectal cancer
samples.
In this study, we have compared the frequency of polymorph-
isms in the NER genes (XPD, XPF, XPG, ERCC1), and in XRCC1
and XRCC3 in colorectal cancer patients and a control group.
Furthermore, for patients heterozygous at any of these loci, we
have looked for LOH in a biopsy of tumour tissue.
MATERIALS AND METHODS
Subjects
Subjects were colorectal cancer patients (mean age 69 years)
attending the Western General Hospital, Edinburgh, UK. Biopsy
material, from cancerous and adjacent noncancerous tissue, was
collected between 1994 and 1997 by Professor Andrew Wyllie for
histology and DNA extraction. At the same time, control blood
samples were selected entirely at random from donors to the
Scottish National Blood Transfusion Service (mean age of donors
is 42 years), and DNA was extracted as described (Tomescu et al,
2001).
PCR and RFLP assays
The polymorphisms studied are shown in Table 1. All, apart from
the XPG exon 15 polymorphism (Emmert et al, 2001), were
originally described by Shen et al (1998). Polymorphisms were
chosen for study because, in each case, the variant allele was
common and the single-nucleotide change resulted in the gain, or
loss, of a restriction site so that the polymorphism could be easily
typed by PCR and RFLP analysis. In addition, significant
associations between some of these polymorphisms and cancer
have previously been reported. Details of the RFLPs are shown in
Table 1. Details of the PCR products, primers and cycle conditions
used are shown in Table 2. Genomic DNA (B100 ng) was
amplified in a 50 ml reaction volume containing 300 ng of each
primer and 2.5 U Taq DNA polymerase (Promega, UK) in 50 mM
KCl, 1.5 mM MgCl2, 10 mM Tris-HCl pH 8.3, 0.45% Triton X-100,
0.45% Tween 20, 0.4 mM Na2EDTA, 0.1 mM dNTPs.
Statistical analysis
We first investigated whether the observed genotype distributions
at each locus were consistent with a Hardy –Weinberg equilibrium.
Having confirmed that this was the case, we assumed that alleles
were independent at each locus, and compared allele counts
among cases and controls. A w2-test with Yates’ correction was
used to give a conservative test for the significance of any
association between a polymorphism and colorectal cancer.
RESULTS
Initially, we set out to genotype a minimum of 40 patient and
control samples for the eight DNA repair gene RFLPs shown in
Table 1. Where less genotypes than this are reported for each
sample group, it is because some genotyping reactions failed. In
the one instance (XRCC3 exon 7), where a significant association
was found during this first round of genotyping, additional patient
and control samples were then genotyped to increase the power of
the statistical analysis. All the genotyping data obtained from the
patient and control samples analysed are presented below. The
patterns obtained for XPF exon 11, XPG exon 15, XRCC1 exon 17
and XRCC3 exon 7 are illustrated in Figure 1. The patterns for the
XPD (exons 6, 22 and 23) and ERCC1 exon 4 polymorphisms have
been described previously (Tomescu et al, 2001). For each
polymorphism investigated in the control and patient groups,
the observed genotype distributions were compared with the
expected frequencies under the Hardy– Weinberg equilibrium. In
each case, there were no significant deviations from the expected
values. We therefore assumed independence of alleles at these loci
and compared allele counts, rather than genotypes, in patient and
control groups because of the resulting increased power of the
statistical analysis.
Table 1 Details of RFLPs studied and fragment sizes
Gene/exon Enzyme Polymorphism Positiona Genotype Fragment sizes (bp)
XPD exon 6 HinfI C to A 22541 CC 288 (no cut)
CA 288+206+82
AA 206+82
XPD exon 22 FokI C to T 35326 CC 229 (no cut)
CT 229+135+94
TT 135+94
XPD exon 23 PstI A to C 35931 AA 234+110
AC 234+172+110+62
CC 172+110+62
ERCC1 exon 4 BsrDI G to A 19007 GG 252 (no cut)
GA 252+179+73
AA 179+73
XPG exon 15 NlaIII G to C 3507 GG 271 (no cut)
(cDNA) GC 271+227+44
CC 227+44
XPF exon 11 AlwNI T to C 30028 TT 442+267
TC 709+442+267
CC 709 (no cut)
XRCC1 exon 17 StuI G to A 36189 GG 343+158
GA 501+343+158
AA 501 (no cut)
XRCC3 exon 7 NlaIII C to T 18067 CC 346 (no cut)
CT 346+242+104
TT 242+104
aNucleotide positions are from the GenBank entries: XPD, L47234; ERCC1, M63796; XPG, NM_000123; XPF, L76568;
XRCC1, L34079; XRCC3, AF037222.
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Lack of association between NER gene polymorphisms and
colorectal cancer
No significant associations were found between the XPD
polymorphisms (exons 6, 22 and 23) and colorectal cancer
(Table 3). Similarly, no significant associations were found for
XPF exon 11, XPG exon 15 and ERCC1 exon 4 (Table 4).
Association between XRCC3 exon 7 polymorphism and
colorectal cancer
Although no significant association with colorectal cancer was
found for the XRCC1 exon 17 polymorphism (Table 5), a
significant association was found for the XRCC3 polymorphism
in the first batch of 40 samples genotyped. This association was
maintained as the sample size of patient and control groups was
increased to over 120, such that the XRCC3 exon 7 C allele was
significantly over-represented in the patient group (odds ratio
(OR) 1.52, 95% confidence interval (CI) 1.04– 2.22, P¼ 0.03).
No LOH at NER gene loci in colorectal cancer
Where normal tissue biopsied from colorectal cancer patients
showed heterozygosity at any of the DNA repair gene loci
genotyped, the tumour tissue from the same patients was analysed
for LOH. The numbers of heterozygous loci examined in the
patients were: 16 for XPD exon 6; 21 for XPD exon 22; 17 for XPD
exon 23; 16 for ERCC1 exon 4; 16 for XPF exon 11; 13 for XPG exon
15; 22 for XRCC1 exon 17; 28 for XRCC3 exon 7. From these 149
heterozygous loci examined, only a single example of LOH was
found. This occurred for an XRCC3 exon 7 CT heterozygote where
the C allele was absent in the tumour (Figure 1).
DISCUSSION
We have investigated the hypothesis that NER gene polymorph-
isms might predispose to colorectal cancer because some forms of
the encoded proteins may be less efficient at repairing DNA
damage arising from exposure of the gut epithelium to genotoxic
compounds in the lumen. NER is known to be active against a
range of bulky DNA lesions in addition to its main role in the
repair of UV-induced DNA damage. In a small study, we have
previously shown a significant association between melanoma and
three polymorphisms in the XPD gene (exon 6 (position 22541) A
Table 2 Details of PCR products for polymorphism analysis
Product Primer sequencea Size (bp) Conditions
XPD exon 6 (F)TGTCCAAAACCCCAGCCAGCTG 288 30 cycles: 941C 1 min, 691C 1 min, 721C 30 s
(R)CAGGGGTCAGGGAGGCTGCCTG
XPD exon 22 (F)AATGACCTTCTGTCCCTGGCCTGCG 229 35 cycles: 941C 1 min, 721C 30 s
(R)AGAAGCTCAGCCTGGGAGGGTGCCG
XPD exon 23 (F)TCAAACATCCTGTCCCTACTGGCCAT 344 35 cycles: 941C 1 min, 671C 1 min, 721C 30 s
(R)CTGCGATTAAAGGCTGTGGACGTGAC
ERCC1 exon 4 (F)TCATCCCTATTGATGGCTTCTGCCC 252 35 cycles: 941C 1 min, 691C 1 min, 721C 30 s
(R)GACCATGCCCAGAGGCTTCTCATAG
XPG exon 15 (F)GACCTGCCTCTCAGAATCATC 271 35 cycles: 941C 1 min, 621C 1 min, 721C 1 min
(R)CCTCGCACGTCTTAGTTTCC
XPF exon 11 (F)TCTCCATGTCCCGCTACTAC 709 35 cycles: 941C 1 min, 671C 1 min, 721C 1 min
(R)GCAGGCACAGGCAAGTTCAA
XRCC1 exon 17 (F)GTCAGTGCTGATTCCCTGATGTGCC 501 35 cycles: 941C 1 min, 691C 1 min, 721C 1 min
(R)CAGATCTCTGACGGAGGTGCCCAGC
XRCC3 exon 7 (F)GCTCGCCTGGTGGTCATCGACTC 346 35 cycles: 941C 1 min, 691C 1 min, 721C 1 min
(R)CTGTCACCTGGAAGAGCACAGTCC
aPrimer sequences were derived from the GenBank entries.
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Figure 1 RFLP analysis of DNA repair gene polymorphisms. The
patterns obtained for the polymorphisms in XPF exon 11, XRCC1 exon 17,
XPG exon 15 and XRCC3 exon 7 are indicated. In each case, the sizes (bp)
of the fragments generated for each genotype by restriction of the PCR
products are shown, along with the uncut PCR product and a molecular
size standard (Std). Details of the digests used and fragment sizes are given
in Table 1. Note that the 44 bp fragment for the XPG assay and the 104 bp
fragment for the XRCC3 assay are not resolved on the gels used. For the
XRCC3 assay, LOH in a colorectal tumour sample is also shown. Normal
tissue from the patient is CT, but the tumour is T.
Table 3 Lack of association of XPD polymorphisms and colorectal
cancer
XPD exon 6 XPD exon 22 XPD exon 23
A C C T A C
Patientsa 41 49 56 34 50 40
Controlsb 56 86 56 32 60 34
OR 1.28, Pc¼ 0.43 OR 0.94, Pc¼ 0.97 OR 0.71, Pc¼ 0.32
(95% CI 0.73–2.27) (95% CI 0.49–1.81) (95% CI 0.38–1.34)
aPatients: n¼ 45. bControls: exon 6, n¼ 71; exon 22, n¼ 44; exon 23, n¼ 47.
cw2 analysis with Yates’, correction.
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allele; exon 22 (position 35326) C allele; exon 23 (position 35931) A
allele) that did not extend to markers flanking the XPD gene
(Tomescu et al, 2001). A similar association for the XPD exons 6
and 23 polymorphisms has been found in some other, but not all,
skin cancer studies (for a review, see Benhamou and Sarasin,
2002). In some studies, the protein encoded by the XPD exon 23A
allele (Lys-Gln change) has been associated with reduced DNA
repair activity (for a review, see Benhamou and Sarasin, 2002). The
XPD exon 23 polymorphism has also been associated with lung
cancer (Chen et al, 2002) and an exon 10 polymorphism with
SCCHN (Sturgis et al, 2002). A polymorphism in the 30 UTR of
ERCC1 (not the exon 4 RFLP studied here) has been associated
with glioma (Chen et al, 2000) and SCCHN (Sturgis et al, 2002) and
two XPA polymorphisms are associated with lung cancer (Park
et al, 2002). Some of the polymorphisms we have studied lead to a
change in the encoded protein (XPD exon 23 Lys-Gln; XPG exon 15
Asp-His; XRCC3 exon 7 Thr-Met), others are silent (XPD exons 6
and 22; XPF exon 11; ERCC1 exon 4; XRCC1 exon 17). A
significant association between a protein variant and cancer only
indicates that the change might be causative. An association with a
silent change indicates that the causative change is closely linked,
but remains to be identified. No significant association was found
between any of the NER gene polymorphisms studied and
colorectal cancer. While this does not exclude the possibility that
NER gene polymorphisms might make a minor contribution to
genetic predisposition to colorectal cancer, a much larger study
than the present one would be required to identify such a minor
risk factor.
Similarly, although polymorphisms in exons 6 and 10 of the
XRCC1 gene, that is involved in BER and the repair of single-
strand DNA breaks, have been associated with colorectal cancer
(reviewed in de Jong et al, 2002) and a range of other internal
cancers (Sturgis et al, 1999; Chen et al, 2002; Duell et al, 2002;
Stern et al, 2002), no association was seen in our study between the
XRCC1 exon 17 polymorphism and colorectal cancer.
A significant association was found for the recombinational
repair gene, XRCC3, where the exon 7 C (position 18067, Thr) allele
showed a modest (OR 1.52), but significant (P¼ 0.03) over-
representation in 123 colorectal cancer patients compared to 128
controls. This XRCC3 exon 7 polymorphism has previously shown
a significant association with melanoma (Winsey et al, 2000),
bladder cancer (Matullo et al, 2001a) and SCCHN (Shen et al,
2002). However, in these studies, it was the variant T (Met) allele
that was over-represented in the cancer patients and this allele has
also been associated with a reduced DNA repair phenotype
(Matullo et al, 2001b).
Conflicting data from association studies between DNA repair
gene polymorphisms and cancer susceptibility, or DNA repair
capacity, are not unusual (e.g. see Benhamou and Sarasin, 2002, for
a review of the XPD data) and many probably result from
insufficient sample sizes or inappropriate choice of controls in
some studies. However, Nelson et al (2002) have considered how
studies on DNA repair gene polymorphisms can produce reliable,
but opposite, associations in different types of cancer. The example
they considered was the XRCC1 Arg399Gln polymorphism. They
suggest that the outcome of a repair variant in a cell may depend
on the selection pressures exerted on that cell. If the polymorph-
ism results in reduced repair efficiency, the resultant increased
levels of DNA damage may lead to an increased rate of apoptosis.
Such a polymorphism would be associated with increased cancer
risk in nondividing, or ‘apoptosis-abrogated’ cells and reduced
cancer risk in cells with the capacity for apoptosis. Nelson et al
(2002) also highlight that high UV exposure to the skin results in
p53 mutant cells which do not apoptose. The variant XRCC3 exon
7 T allele with reduced repair capacity could result in an increased
cancer risk in the skin (by the fixation of mutations in p53 mutant
cells) and a protective effect in the gut (by more efficient
apoptosis).
The mechanism for the reduced repair capacity associated with
the variant XRCC3 exon 7 T allele is unknown. It may alter the
protein’s interaction with RAD51, but could also affect other
aspects of the role of XRCC3. This highlights the main difficulty
with studies designed to look at single polymorphisms without
knowledge of their functional significance. Without detailed
knowledge of XRCC3’s roles in DNA repair, it is hard to
evaluate the significance of such studies, or exclude a role for
confounding factors. In the same way as we have done for XPD
and melanoma (Tomescu et al, 2001), study of XRCC3
flanking markers will be required to rule out roles for linkage
disequilibrium and population stratification in the association
found.
Our study suggested that LOH of NER genes and XRCC1 and
XRCC3 does not play an important role in colorectal carcinogen-
esis. Indeed, only a single example of LOH was found (for XRCC3)
in 149 heterozygous loci examined. In addition to reporting a high
rate of LOH for NER genes in ovarian and lung cancer,
Takebayashi et al (2001) reported LOH for NER genes in 16.7%
of colon carcinomas. Closer examination of their data reveals that
this equates to LOH for XPE in a single patient and LOH
for XPB and XPE in a second patient, from a total of 12
patients examined and eight NER genes typed (44 out of 96
assays were noninformative). Thus, the two studies are in
agreement that the frequency of LOH for NER genes is low in
colorectal cancer.
In conclusion, association and LOH studies suggest that NER
genes are not important genetic determinants for colorectal
carcinogenesis. A modest association between colorectal cancer
and a polymorphism in the recombination repair gene XRCC3 was
found, but additional studies will be required to evaluate its
importance.
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Table 4 Lack of association of NER polymorphisms and colorectal
cancer
XPF exon 11 XPG exon 15 ERCC1 exon 4
T C C G G A
Patientsa 61 19 13 67 38 52
Controlsb 57 9 22 58 58 86
OR 0.51, P¼ 0.18 OR 0.51, P¼ 0.13 OR 1.08, P¼ 0.87
(95% CI 0.19–1.30) (95% CI 0.22–1.18) (95% CI 0.61–1.92)
aPatients: XPF and XPG, n¼ 40; ERCC1, n¼ 45. bControls: XPF, n¼ 33; XPG, n¼ 40;
ERCC1, n¼ 72.
Table 5 Association of XRCC3 exon 7 C allele and colorectal cancer
XRCC1 exon 17 XRCC3 exon 7
G A C T
Patientsa 40 40 161 85
Controlsb 38 28 142 114
OR 0.74, P¼ 0.46 OR 1.52, P¼ 0.03
(95% CI 0.36–1.50) (95% CI 1.04–2.22)
aPatients: XRCC1, n¼ 40; XRCC3, n¼ 123. bControls: XRCC1, n¼ 33; XRCC3,
n¼ 128.
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